HEALTH TECHNOLOGY ASSESSMENT, PRICE AND REIMBURSEMENT REVIEW FOR ORPHAN DRUGS IN ITALY

被引：1
|
作者：
Tavella, F. [1 ]
Korchagina, D. [2 ]
Rodrigues, J. [2 ]
Remuzat, C. [2 ]
机构：
[1] Creativ Ceut, London, England
[2] Creativ Ceut, Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1733
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY103
引用
收藏
页码：A540 / A540
页数：1
相关论文
共 50 条
  • [1] Pricing and reimbursement of orphan drugs in Italy
    Lopatriello, S.
    Schivazappa, C.
    Negrini, C.
    Berto, P.
    VALUE IN HEALTH, 2006, 9 (06) : A208 - A209
  • [2] Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
    Krzysztof Piotr Malinowski
    Paweł Kawalec
    Wojciech Trąbka
    Christoph Sowada
    Guenka Petrova
    Manoela Manova
    Alexandra Savova
    Pero Draganić
    Juraj Slabý
    Agnes Männik
    Kristóf Márky
    Zinta Rugaja
    Jolanta Gulbinovic
    Tomas Tesar
    Marian Sorin Paveliu
    Orphanet Journal of Rare Diseases, 15
  • [3] Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
    Malinowski, Krzysztof Piotr
    Kawalec, Pawel
    Trabka, Wojciech
    Sowada, Christoph
    Petrova, Guenka
    Manova, Manoela
    Savova, Alexandra
    Draganic, Pero
    Slaby, Juraj
    Mannik, Agnes
    Marky, Kristof
    Rugaja, Zinta
    Gulbinovic, Jolanta
    Tesar, Tomas
    Paveliu, Marian Sorin
    ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [4] COMPARATIVE ANALYSIS OF HTA DECISIONS, PRICE AND REIMBURSEMENT LEVEL OF ORPHAN DRUGS IN FRANCE AND ITALY
    Korchagina, D.
    Tavella, F.
    Remuzat, C.
    Kornfeld, A.
    Toumi, M.
    VALUE IN HEALTH, 2014, 17 (07) : A539 - A540
  • [5] THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES
    Nicholson, L.
    Langham, S.
    Adkins, E.
    VALUE IN HEALTH, 2019, 22 : S860 - S860
  • [6] Analysing criteria for price and reimbursement of orphan drugs in Spain
    Badia, Xavier
    Gil, Alicia
    Luis Poveda-Andres, Jose
    Shepherd, John
    Tort, Marina
    FARMACIA HOSPITALARIA, 2019, 43 (04) : 121 - 127
  • [7] CLINICAL AND ECONOMIC EVIDENCE THRESHOLDS FOR ORPHAN DRUGS: ARE REQUIREMENTS FOR FAVORABLE HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT ON THE RISE?
    Shih, A. Y.
    Duong, A.
    Tao, C.
    Ransom, J. F.
    Spinner, D. S.
    White, C.
    Doyle, J. J.
    Faulkner, E. C.
    VALUE IN HEALTH, 2013, 16 (03) : A108 - A108
  • [8] EARLY BENEFIT ASSESSMENT OF ORPHAN DRUGS IN GERMANY: METHODOLOGICAL CHALLENGES AND IMPLICATIONS ON REIMBURSEMENT PRICE
    Schneider, D.
    Bot, D.
    Ecker, T.
    VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
  • [9] Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing
    Rawson, Nigel S. B.
    Adams, John
    EXPERT OPINION ON ORPHAN DRUGS, 2024, 12 (01): : 1 - 11
  • [10] ORPHAN DRUGS: HEALTH TECHNOLOGY ASSESSMENT AND PRICING IN EUROPE
    Jaroslawski, S.
    Toumi, M.
    Korchagina, D.
    Jadot, G.
    VALUE IN HEALTH, 2018, 21 : S24 - S24
12345